Unknown

Dataset Information

0

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine.


ABSTRACT: The changes in the severe acute respiratory syndrome coronavirus 2 and the tapering of immunity after vaccination have propelled the need for a booster dose vaccine. We aim to evaluate B and T cell immunogenicity and reactogenicity of mRNA-1273 COVID-19 vaccine (100 µg) as a third booster dose after receiving either two doses of inactivated COVID-19 vaccine (CoronaVac) or two doses of viral vector vaccine (AZD1222) in adults not previously infected with COVID-19. The anti-receptor-binding-domain IgG (anti-RBD IgG), surrogate virus neutralization test (sVNT) against the Delta variant, and Interferon-Gamma (IFN-γ) level were measured at baseline, day (D)14 and D90 after vaccination. In D14 and D90, the geometric means of sVNT were significantly increased to 99.4% and 94.5% inhibition in CoronaVac, respectively, whereas AZD1222 showed inhibition of 99.1% and 93%, respectively. Anti-RBD IgG levels were 61,249 to 9235 AU/mL in CoronaVac and 38,777 to 5877 AU/mL in AZD1222 after D14 and D90 vaccination. Increasing median frequencies of S1-specific T cell response by IFN-γ concentration were also elevated in D14 and were not significantly different between CoronaVac (107.8-2035.4 mIU/mL) and AZD1222 (282.5-2001.2 mIU/mL). This study provides evidence for the high immunogenicity of the mRNA-1273 booster after two doses of CoronaVac or AZD1222 in the Thai population.

SUBMITTER: Tangsathapornpong A 

PROVIDER: S-EPMC10053262 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine.

Tangsathapornpong Auchara A   Nanthapisal Sira S   Pontan Kanassanan K   Bunjoungmanee Pornumpa P   Neamkul Yamonbhorn Y   Boonyarangkul Arthit A   Wanpen Supattra S   Fukpho Waraphon W   Jitpokasem Sumana S   Tharabenjasin Phuntila P   Jaru-Ampornpan Peera P  

Vaccines 20230227 3


The changes in the severe acute respiratory syndrome coronavirus 2 and the tapering of immunity after vaccination have propelled the need for a booster dose vaccine. We aim to evaluate B and T cell immunogenicity and reactogenicity of mRNA-1273 COVID-19 vaccine (100 µg) as a third booster dose after receiving either two doses of inactivated COVID-19 vaccine (CoronaVac) or two doses of viral vector vaccine (AZD1222) in adults not previously infected with COVID-19. The anti-receptor-binding-domain  ...[more]

Similar Datasets

2022-10-19 | GSE206023 | GEO
| S-EPMC8639402 | biostudies-literature
| S-EPMC8779615 | biostudies-literature
2024-01-31 | GSE234008 | GEO
| S-EPMC9393164 | biostudies-literature
2024-04-01 | GSE249050 | GEO
| S-EPMC9634958 | biostudies-literature
| S-EPMC4539908 | biostudies-literature